Method for establishing a scoring system for evaluating spontaneous pathological necrosis of liver cancer
By establishing a scoring system for spontaneous pathological necrosis assessment and scoring of liver cancer, the problem of spontaneous pathological necrosis assessment in liver cancer treatment was solved, and guidance on prognosis evaluation and treatment decisions after TACE and liver transplantation was achieved, improving the accuracy of treatment and patient survival time. .
Patent Information
- Application Number
- CN202210833809.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-14
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-07-14
AI Technical Summary
The prior art is difficult to accurately evaluate spontaneous pathological necrosis in the treatment of liver cancer, resulting in the unpredictable risk of recurrence after adjuvant treatment such as TACE and liver transplantation, affecting the treatment effect and patient survival.
Establish a scoring system for the evaluation and scoring of spontaneous pathological necrosis of liver cancer. By obtaining and staining liver cancer pathological tissue samples, the pathological sections are made, the liver cancer necrosis score is calculated based on the necrosis score, and the treatment effect and survival conditions under different necrosis states are analyzed. Kaplan is used –Meier survival curve and Log-rank test, combine R language to build prediction models to improve prediction accuracy.
This system can effectively guide HCC patients to receive postoperative adjuvant TACE treatment, predict the risk of recurrence after liver transplantation, improve the prognosis and survival of treatment, and enhance the accuracy and individualization of liver cancer treatment.
Smart Images

Figure CN115144589B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of clinical medicine, and more particularly to a method for establishing an evaluation and scoring system for spontaneous pathological necrosis of liver cancer. Background Art
[0002] Hepatocellular carcinoma (HCC) is the seventh most common malignant tumor in the world today, and its mortality rate ranks third. HCC is highly malignant, with an overall 5-year survival rate of less than 15%. Even after R0 resection, more than half of the patients still relapse. Liver cancer shows high heterogeneity both inside and outside the tumor, and different prognoses are one of the manifestations of its heterogeneity. Transcatheter arterial chemoembolization (TACE) has been more widely used as an adjuvant therapy before or after surgery. Previous studies have reported that adjuvant TACE can prolong the survival of patients with BCLC grade B and high risk of recurrence, but in fact more than 40% of liver cancer patients do not respond to TACE treatment. There is also a lot of evidence that TACE can cause an increase in serum AFP and a decrease in albumin, thereby causing irreversible liver damage and even liver failure. Liver transplantation is the best radical treatment for liver cancer, especially as the standard of treatment for early HCC, but liver transplantation still has the problem of liver shortage and the risk of recurrence. More reasonable selection of transplant recipients and prevention of recurrence in high-risk groups are hot topics that are constantly being studied and updated. Therefore, individualized solutions are the research direction of precision treatment of liver cancer. Summary of the invention
[0003] In view of this, the present invention provides a method for establishing an evaluation scoring system for spontaneous pathological necrosis of liver cancer. Through the impact of the newly discovered biomarker of spontaneous pathological necrosis of hepatocellular carcinoma on the prognosis of liver cancer, it can be used to guide and provide different diagnosis and treatment plans for liver cancer, and further realize the precision treatment of liver cancer.
[0004] In order to achieve the above object, the present invention adopts the following technical solution:
[0005] A method for establishing an evaluation scoring system for spontaneous pathological necrosis of liver cancer comprises the following steps:
[0006] Obtain liver cancer pathological tissue samples;
[0007] The liver cancer pathological tissue sample is stained with H&E to prepare a pathological section;
[0008] The necrosis score of the slice was determined under a microscope according to the characteristics and extent of its pathological manifestations;
[0009] The liver cancer necrosis score was calculated based on the section necrosis score.
[0010] Optionally, it also includes analyzing the differences in survival of patients with or without postoperative adjuvant TACE treatment and liver transplantation for liver cancer in different states of liver cancer necrosis.
[0011] Optionally, the correlation between treatment and survival under different tumor micronecrosis conditions is also analyzed based on the necrosis score.
[0012] Optionally, the liver cancer necrosis score is calculated based on the slice necrosis score as follows:
[0013] Patients with liver cancer at different micronecrosis levels were divided into groups according to whether or not TACE was performed, and the Kaplan–Meier survival curves were drawn and the Log-rank test was performed to find the significant difference between the two groups.
[0014] The Kaplan–Meier survival curves were drawn for the prognosis of liver cancer patients with different degrees of micronecrosis and the Log-rank test was used to obtain significant differences. A prediction model was constructed using R language to improve the AUC values of the Milan criteria, end-stage liver disease model and alpha-fetoprotein levels.
[0015] It can be seen from the above technical solutions that, compared with the prior art, the present invention discloses a method for establishing a scoring system for evaluating spontaneous pathological necrosis of liver cancer, which can be used to guide HCC patients who have undergone R0 resection to accept postoperative adjuvant TACE treatment. It also provides the predictive significance of this biomarker for long-term recurrence after liver transplantation, which further helps guide whether patients with liver cancer should accept adjuvant treatment after liver transplantation. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.
[0017] Figure 1 This is a schematic diagram of the necrosis scoring determination of pathological sections of liver cancer micronecrosis according to the present invention;
[0018] Figure 2 This is a schematic diagram of the difference in prognosis between patients with and without postoperative adjuvant TACE in different necrosis conditions;
[0019] Figure 3 This is a schematic diagram showing that patients with liver cancer have significantly different prognoses after liver transplantation under different necrosis conditions;
[0020] Figure 4 Schematic diagram of ROC curve and AUC for improving the prediction ability of tumor micronecrosis after liver transplantation recurrence. DETAILED DESCRIPTION
[0021] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0022] The embodiment of the present invention discloses a method for establishing an evaluation and scoring system for spontaneous pathological necrosis of liver cancer, and its guiding significance for the application of postoperative adjuvant TACE for liver cancer and postoperative adjuvant therapy for liver cancer transplantation. The samples were obtained from 897 surgical resections and 370 liver transplantation liver cancer pathological tissue specimens from an affiliated hospital of Zhejiang University School of Medicine during 2014-2018. The samples were collected in accordance with the requirements of the "Standardized Pathological Diagnosis Guidelines for Primary Liver Cancer (2015 Edition)". After H&E staining, the samples were made into pathological sections, and the necrosis score of the sections was determined under a microscope according to the characteristics and range of their pathological manifestations; the liver cancer necrosis score was calculated based on the necrosis score of the sections. The differences in the survival of patients with or without postoperative adjuvant TACE treatment and liver transplantation for liver cancer under different necrosis states were further analyzed, and finally the guiding significance of this biomarker for the use of postoperative adjuvant TACE for liver cancer and adjuvant therapy after liver transplantation was provided.
[0023] HCC patients were grouped according to different necrosis scores, and the prognostic correlation of postoperative adjuvant TACE treatment with or without postoperative necrosis was analyzed, further providing guidance for the use of adjuvant TACE after liver cancer surgery and adjuvant therapy after liver transplantation. The retrospective data used for analysis were statistically verified and had a large sample size and a long follow-up time.
[0024] Furthermore, this prognostic relevance will be validated by rigorously designed prospective clinical trials.
[0025] The specific evaluation and guidance methods are as follows: The specimens of liver cancer resection surgery are collected according to the requirements of the "Standardized Pathological Diagnosis Guidelines for Primary Liver Cancer (2015 Edition)" and scored using the micronecrosis scoring system. Patients with micronecrosis scores of 1 and 2 are re-evaluated for recurrence after 1 month. If there is no recurrence, postoperative adjuvant TACE treatment is performed within 4-8 weeks after surgery. Adjuvant treatment is performed for patients with micronecrosis after liver transplantation to prevent recurrence.
[0026] In this example, 897 surgical resections and 370 liver transplantation liver cancer pathological tissue specimens from an affiliated hospital of Zhejiang University School of Medicine during 2014-2018 were processed as follows, and the scoring system and guidance method are as follows:
[0027] (1) Definition: Micronecrosis is defined as coagulative necrosis of local tissues and cells observed under a microscope. Due to the shrinkage and fragmentation of the cell nucleus and the eosinophilic changes in the cytoplasm, the pathological manifestation is red staining of the cytoplasm in H&E sections.
[0028] (2) Pathological tissue specimens (5 tumors) from surgical resection specimens of primary liver cancer patients who had not received anti-tumor treatment were selected. After H&E staining, the slide necrosis score (SNS) was determined based on the pathological characteristics and range. The SNS grading criteria are as follows:
[0029] SNS = 0, necrosis area ≤ 5%;
[0030] SNS = 1, 5% < necrotic area ≤ 20%;
[0031] SNS = 2, 20% < necrotic area ≤ 50%;
[0032] SNS=3, necrotic area>50%.
[0033] Specific pathological manifestations such as Figure 1 shown.
[0034] (3) According to the slice necrosis score in (2), calculate the liver cancer necrosis score (Necrosis Score, Nscore). The grading standard of Nscore is as follows:
[0035] Nscore=0, all slices SNS=0;
[0036] Nscore = 1, ≥1 slice SNS = 1 and ≤1 slice SNS = 2;
[0037] Nscore = 2, ≥2 slices SNS = 2 or only 1 slice SNS = 3;
[0038] Nscore=3, SNS=3 for ≥2 slices.
[0039] (4) The 897 patients with HCC who underwent surgical resection were divided into the non-micronecrosis group, micronecrosis group, Nscore = 1 group, and Nscore = 2 group according to the above scoring system. The prognostic differences between patients who underwent postoperative TACE and those who did not were analyzed in the two groups. Figure 2 shown.
[0040] Grouping Number of people Percentage of total number of people Number of patients undergoing TACE after surgery Percentage Micronecrosis(-) 480 53.5% 238 49.6% Micronecrosis(+) 417 46.5% 236 56.6% Nscore=1 293 32.7% 155 52.9% Nscore = 2 124 13.8% 81 65.3%
[0041] In the Micronecrosis (+) and Nscore = 2 groups, there was a statistically significant difference in the prognosis between patients who received TACE and those who did not, and TACE improved the prognosis. In the two groups, P = 0.003 and P < 0.001, respectively.
[0042] (5) Cox regression analysis showed that postoperative TACE was an independent risk factor affecting prognosis in patients with micronecrosis (HR=0.559, P=0.008). Based on the results obtained, the clinical treatment plan guidance is proposed: postoperative adjuvant TACE can improve the prognosis of patients with micronecrosis, especially those with a micronecrosis score of 2. The conclusion will also be verified in prospective clinical studies; while postoperative adjuvant TACE will reduce the prognosis of patients without micronecrosis.
[0043] (6) The 370 liver transplant patients included in the study were divided into a non-micronecrosis group and a micronecrosis group according to the above scoring system. Patients who had received preoperative anti-tumor treatment were further excluded to obtain 116 liver transplant patients with primary pathological necrosis, who were divided into four groups with scores of 0, 1, 2, and 3. The prognostic differences among the patients in each group were analyzed. Survival curve analysis is shown in Figure 2. Figure 3 shown.
[0044] Grouping Number of people Percentage Micronecrosis(-) 64 17.3% Micronecrosis(+) 306 82.7%
[0045] The survival curve analysis of the two groups of patients showed significant statistical difference, with recurrence-free survival P=0.037.
[0046] Grouping Number of people Percentage Nscore = 0 36 31.0% Nscore=1 44 37.9% Nscore = 2 26 22.4% Nscore=3 10 8.6%
[0047] The survival curve analysis of the four groups of patients showed significant statistical differences, with recurrence-free survival P=0.004 and overall survival P=0.019.
[0048] (7) The R language was used to calculate the predictive ability of the commonly used indicators for predicting the prognosis of liver transplantation: Milan criteria, end-stage liver disease model, and alpha-fetoprotein level after incorporating micronecrosis. The main results were as follows: the Milan criteria increased from 0.705 to 0.738, the end-stage liver disease model increased from 0.682 to 0.738, and the alpha-fetoprotein level increased from 0.566 to 0.664. The ROC curve is shown in Figure 2. Figure 4 shown.
[0049] The present invention is applicable to the application of primary pathological necrosis of tumor based on micronecrosis scoring system in patients with liver cancer, including but not limited to: application in guiding auxiliary TACE treatment after radical resection of liver cancer; application in assessing the risk of recurrence after liver transplantation and guiding subsequent treatment decisions.
[0050] In this specification, each embodiment is described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the embodiments can be referred to each other. For the device disclosed in the embodiment, since it corresponds to the method disclosed in the embodiment, the description is relatively simple, and the relevant parts can be referred to the method part.
[0051] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A method for establishing a scoring system for evaluating spontaneous pathological necrosis of liver cancer, characterized in that: The following steps are involved: Obtain liver cancer pathological tissue samples; The liver cancer pathological tissue sample is stained with H&E to prepare a pathological section; The necrosis score of the slice was determined under a microscope according to the characteristics and extent of its pathological manifestations; The liver cancer necrosis score was calculated based on the section necrosis score; The grading criteria for the necrosis score are as follows: SNS = 0, necrosis area ≤ 5%; SNS=1, 5%<necrotic area≤20%; SNS=2, 20%<necrotic area≤50%; SNS=3, necrosis area>50%; The grading criteria for the liver cancer necrosis score are as follows: Nscore=0, all slices SNS=0; Nscore=1, ≥1 slice SNS=1 and ≤1 slice SNS=2; Nscore=2, ≥2 slices SNS=2 or only 1 slice SNS=3; Nscore=3, ≥2 slices SNS=3; Patients were grouped according to the above scores: Patients with liver cancer at different micronecrosis levels were divided into groups according to whether TACE was performed or not, and the Kaplan–Meier survival curve was drawn and the Log-rank test was performed to find the significant difference between the two groups. The Kaplan–Meier survival curves were drawn for the prognosis of liver cancer patients with different degrees of micronecrosis and the Log-rank test was used to obtain significant differences. A prediction model was constructed using R language to improve the AUC values of the Milan criteria, end-stage liver disease model and alpha-fetoprotein levels.
2. The method for establishing a scoring system for evaluating spontaneous pathological necrosis of liver cancer according to claim 1, characterized in that: It also includes analysis of the differences in survival of patients with or without postoperative adjuvant TACE treatment and liver transplantation for liver cancer in different states of liver cancer necrosis.
3. The method for establishing a scoring system for evaluating spontaneous pathological necrosis of liver cancer according to claim 1, characterized in that: It also includes analysis of the correlation between treatment and survival under different tumor micronecrosis conditions based on necrosis scores.
